Evaluation of a Nutraceutical for Endometriosis Pain Relief

A Single Center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of a Specialized Nutraceutical for Endometriosis

Based on the EHP-30 questionnaire, the pain score and general well-being of all patients will be assessed with and without taking a specialized nutraceutical. These patients will be taking continuous oral contraception, for 3 months before inclusion till at least end of the study or not taking any oral contraception at all during the study due to contraindication(s).

Inclusion Criteria:

• Confirmed endometriosis and/or Positive NMR
• 18-49y
• Mean pain score >6 on the assessment of pelvic pain (Visual analogue scale)
• Not eligible for surgery in the coming 3 months or had surgery >3 months before inclusion in the study
• >3 months intake of continue oral contraception (Oestrogen/Progesterone) before inclusion or no intake of oral contraception due to contraindication
• Has given voluntary, written, informed consent to participate in the study.

Exclusion Criteria:

• Planned surgery during study
• <3 month intake of continue oral contraception (Oestrogen/Progesterone) before inclusion
• Chronic inflammatory disease (Chron's disease, Rheumatism,..)
• Pregnancy
• Bariatric surgery
• Malabsorption issues
• Allergy or hypersensitivity to the study product:
• Fish and products thereof: fish oil
• Soybeans and products thereof
• Alcohol or substance abuse
• Start of gonadorelin analogue (ex. Busereline, Gosereline, triptoreline) therapy in the past 6 months
• Intake of other food supplements, including omega 3 and omega 6
• Any other condition which in the investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject